This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Reunion Neuroscience (REUN) Stock Overview

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. More details

REUN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue (CA$0)

Highly volatile share price over the past 3 months

Has less than 1 year of cash runway

Does not have a meaningful market cap ($17M)

REUN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW445,595 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

445,595 investors already sharing narratives

View all narratives

Reunion Neuroscience Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Reunion Neuroscience
Historical stock prices
Current Share Price	CA$1.12
52 Week High	CA$7.62
52 Week Low	CA$0.63
Beta	4.21
1 Month Change	0.90%
3 Month Change	45.47%
1 Year Change	-72.96%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-89.05%

Recent updates

Seeking Alpha • Oct 07

Reunion Neuroscience announces resignation of director, general counsel

Reunion Neuroscience (NASDAQ:REUN) on Friday announced the resignations of director Ronan Levy and general counsel & corporate secretary Paula Amy Hewitt. The company appointed CEO Greg Mayes to replace Levy as director. CFO Donna Wong as appointed as corporate secretary in place of Hewitt. REUN stock +4.9% to $1.94 after hours.

Seeking Alpha • Sep 28

Reunion Neuroscience appoints Greg Mayes as President and CEO

Reunion Neuroscience (NASDAQ:REUN) appoints Greg Mayes as President and Chief Executive Officer. Most recently he served as the President and CEO of Antios Therapeutics. It is anticipated that Mr. Mayes will be appointed to the Reunion Board of Directors to replace Ronan Levy, Reunion co-founder and current Chairman and CEO of Field Trip Health & Wellness Ltd., who will step down from Reunion’s Board in October 2022.

Seeking Alpha • Aug 15

Field Trip Health  GAAP EPS of -C$0.09

Field Trip Health press release (NASDAQ:FTRP): Q1 GAAP EPS of -C$0.09. As of June 30, 2022, the Company had unrestricted cash, cash equivalents and short-term investments of C$52.3 million, including C$4.1 million held at the Clinic Operations. Shares +4.42% AH.

Seeking Alpha • Jun 29

Field Trip Health receives final court approval for clinics business spin-out

Psychedelic therapies company Field Trip Health (NASDAQ:FTRP) said it has received final court approval for the spin-out of its clinics business to Field Trip Health & Wellness. The spin-out is to be executed by way of a plan of arrangement, with the closing subject to regulatory approvals. As part of the arrangement, each share of FTRP will be exchanged for one common share of FTRP, to be renamed Reunion Neuroscience on consummation of the arrangement, and ~0.86 common share of Field Trip Health & Wellness. The closing of the arrangement is set to occur on or around August. Field Trip Health & Wellness will list on the TSX Venture Exchange, subject to the exchange's approval. Additionally, Field Trip Health closed a private placement of subscription receipts of Field Trip Health & Wellness. The private placement, led by Bloom Burton Securities, involved an issue price of C$0.50 per receipt, with aggregate gross proceeds of C$2.1M. The net proceeds of the offering will be used for clinic operating expenses, working capital, arrangement expenses as well as for general corporate purposes. Source: Press Release

Shareholder Returns

	REUN	US Biotechs	US Market
7D	0.9%	-3.1%	-1.6%
1Y	-73.0%	37.2%	12.1%

Return vs Industry: REUN underperformed the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: REUN underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is REUN's price volatile compared to industry and market?
REUN volatility
REUN Average Weekly Movement	17.1%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.8%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.9%

Stable Share Price: REUN's share price has been volatile over the past 3 months.

Volatility Over Time: REUN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2008	16	Greg Mayes	reunionneuro.com

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company’s lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications.

Reunion Neuroscience Inc. Fundamentals Summary

How do Reunion Neuroscience's earnings and revenue compare to its market cap?
REUN fundamental statistics
Market cap	US$12.47m
Earnings (TTM)	-US$28.55m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is REUN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REUN income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$38.10m
Earnings	-CA$38.10m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-3.25
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did REUN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/08/03 09:32
End of Day Share Price	2023/07/31 00:00
Earnings	2023/03/31
Annual Earnings	2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Reunion Neuroscience Inc. is covered by 7 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Martin	Bloom Burton & Co.
Elemer Piros	D. Boral Capital LLC.
Patrick Trucchio	H.C. Wainwright & Co.

This company has been acquired

Reunion Neuroscience (REUN) Stock Overview

Risk Analysis

Join community and earn perks

Reunion Neuroscience Inc. Competitors

CytoMed Therapeutics

Palatin Technologies

Fresh Tracks Therapeutics

Bolt Biotherapeutics

Price History & Performance

Recent News & Updates

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. announced that it has received CAD 103 million in funding from a group of investors

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. Files Form 15

MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.

Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023

Recent updates

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. announced that it has received CAD 103 million in funding from a group of investors

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. Files Form 15

MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.

Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023

New major risk - Financial position

MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction.

Reunion Neuroscience Inc. to Report Q3, 2023 Results on Feb 14, 2023

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic Re104

High number of new directors

High number of new and inexperienced directors

Reunion Neuroscience announces resignation of director, general counsel

Reunion Neuroscience appoints Greg Mayes as President and CEO

High number of new and inexperienced directors

Field Trip Health&nbsp; GAAP EPS of -C$0.09

Field Trip Health receives final court approval for clinics business spin-out

High number of new directors

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings released: CA$0.23 loss per share (vs CA$0.16 loss in 2Q 2021)

Less than half of directors are independent

Less than half of directors are independent

First quarter 2022 earnings released: CA$0.22 loss per share (vs CA$1.69 loss in 1Q 2021)

Less than half of directors are independent

Shareholder Returns

Price Volatility

About the Company

Reunion Neuroscience Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources

Field Trip Health GAAP EPS of -C$0.09